NanoViricides 9/27/2024 Earnings Report

NanoViricides EPS Results

• Actual EPS: -$0.19
• Consensus EPS: -$0.20
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

NanoViricides Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NanoViricides Announcement Details

• Date: 9/27/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

NanoViricides (NYSE:NNVC) is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses. Its lead influenza program has demonstrated promising results in animal models, supporting the potential for reduced viral loads and improved survival outcomes. NanoViricides also pursues combination strategies that leverage its nanoviricide constructs alongside standard antiviral agents to enhance efficacy and limit the emergence of resistance.

R&D activities are conducted primarily at the company’s facilities in Shelton, Connecticut, with supplemental collaborations through contract research organizations in the United States and abroad. NanoViricides maintains manufacturing partnerships to support scale-up of its nanomedicine formulations under current Good Manufacturing Practice (cGMP) guidelines. The company continually seeks strategic alliances and licensing opportunities to advance its technology across multiple viral indications and geographic markets.

Founded in 2005, NanoViricides operates under the leadership of its founder and Chief Executive Officer, Dr. Anil R. Diwan. The company’s management team draws on interdisciplinary expertise in virology, nanotechnology and pharmaceutical development. With a commitment to addressing unmet medical needs in infectious diseases, NanoViricides aims to progress its clinical candidates toward regulatory milestones and potential commercial adoption.